Application Value of PCSK9 Inhibitor in Cardiovascular High Risk Patients: A Meta-Analysis.

ABSTRACT:

Background

Proprotein convertase subtilisin / Kexin type 9 (PCSK9) inhibitors are efficacious lipid-lowering agents. This drug is related to improving the prognosis of patients with cardiovascular disease (CVD). The purpose of this meta-analysis was to systematically analyze the safety and efficacy of PCSK9 inhibitors in all published randomized controlled trials (RCTs).

Methods

As of October 25, 2021, we searched PubMed, EMBASE, MEDLINE, Cochrane Library and web of science.

Results

From 684 articles, we included 11 trials for meta-analysis, including 52511 participants (26938 in the PCSK9 inhibitor group and 25573 in the control group). In terms of effectiveness, PCSK9 inhibitors reduced the risk of major adverse cardiovascular events(MACE) (OR=0.89, 95% Cl: 0.83-0.9

SUBMITTER: Zhao L 

PROVIDER: S-EPMC10362201 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature